Skip to content

The Influence of Trained Immunity in COVID-19 Vaccinated Individuals

The Influence of Trained Immunity in COVID-19 Vaccinated Individuals

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05705180
Enrollment
600
Registered
2023-01-30
Start date
2022-12-01
Completion date
2024-12-01
Last updated
2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccination; Infection, Zoster Varicella

Brief summary

The concept of trained immunity defines the long-term functional reprogramming of innate immune cells, which is evoked by exogenous or endogenous insults and leads to an altered response towards a second challenge after return to a non-activated state and is characterized by several markers, such as specific cytokines, activation markers of innate immune cells and epigenetic modifications, e.g. H3K4me3. Vaccinations have been shown to induce trained immunity and to have heterologous effects on other infections or vaccinations. A recent article showed, that individuals who had received recombinant adjuvanted zoster vaccine (RZV) before the pandemic had a 16% lower risk of COVID-19 diagnosis and a 32% lower risk of hospitalization suggesting a protective heterologous effect of RVZ on COVID19 infections. So far, the mechanisms behind these add-on benefits of RZV vaccination are on the hypothetical level and need further experimental evidence. Therefore, we aim to investigate the specific humoral and cellular immune response towards COVID-19 vaccine in healthy individuals who were exposed to RZV 1 to 12 months before COVID-19 vaccination compared to individuals who did not receive RZV before. Particular emphasis is layed on COVID-19 vaccine non-responders and individuals with breakthrough infections indicating lower vaccine efficacy compared to those who had no breakthrough infection. The primary objective is the cytokine profile of spike protein-stimulated T, NK and NKT cells. Spike protein stimulated T, NK and NKT cells are characterized by cell surface markers, transcription factor expression, chemokine receptor expression, activation and proliferation markers and by their lineage-specific cytokine pattern. CD14+ monocytes are magnetically isolated and further characterized by cell-culture experiments imitating a training and resting period after stimulation. Epigenetic modifications by methylation of CpG regions are assessed at promoter, enhancer and regulatory gene regions of immune cell characteristic transcription factors by bisulfite conversion and pyrosequencing. Chromatin immunoprecipitation and ChIP-seq will be performed for analysis H3K4me3 associated with trained immunity. Humoral and cellular reactivity to spike protein is analyzed by adapted ELISA and neutralisation assays and by ELISpot and flow cytometry, respectively, and correlated. From our findings we expect to learn about the role of previous RZV on immunogenicity and efficacy of COVID-19 vaccination and whether mechanisms of trained immunity play a role for better responses towards COVID-19 vaccination.

Interventions

BIOLOGICALrecombinant adjuvanted zoster vaccine

vaccination with recombinant adjuvantes zoster vaccine

Sponsors

Wuerzburg University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

Group 1, retrospective (samples already stored, CoVaKo study cohort): healthy (n=420) Group 2, prospective (samples to be recruited, CoVaKo study cohort): healthy (n=180) * Age 18-90 years, stratified into \<60 and ≥60 years * at least 2 COVID-19-mRNA vaccinations as equivalent to primary immunization and the third and/or fourth dose considered as booster, as recommended for all individuals \>12 years (third dose) and for risk groups, medical staff, nursing home residents (fourth dose) in Germany Only individuals naive for SARS-CoV-2 (negative N-specific and S-specific-IgG antibody status, no history of PCR+ swab) before COVID-19 vaccination will be included.

Exclusion criteria

* High-dose glucocorticoids \>10 mg/day * Immunosuppressive therapy * Biologics or immunomodulators * Transplantation * Cancer * Autoimmunity * RZV after COVID-19 vaccination * COVID-19 PCR+ before COVID-19 vaccination * Other types of COVID-19 vaccines than mRNA vaccines

Design outcomes

Primary

MeasureTime frameDescription
Interferon-gamma12 monthsSpot forming units in Interferon-gamma ELISpot assay

Secondary

MeasureTime frameDescription
Spike-specific IgG antibodies12 monthsSpike-specific IgG antibodies measured in BAU/ml
Spike-specific IgG antibody avidity12 monthsSpike-specific IgG antibody avidity measured in relative avidity by adapted ELISA

Countries

Germany

Contacts

Primary ContactMartina Prelog, Prof. Dr.
Prelog_M@ukw.de093120127708

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026